SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
aa	Amino acids
ACE2	Angiotensin-converting enzyme 2
Alum	Alhydrogel adjuvant 2%
AS03	Adjuvant System 03
BHK	Baby hamster kidney
BHK-hACE2	BHK cells stably expressing human ACE2
BPL	β-propiolactone
CT	Cytoplasmic tail
DMEM	Dulbecco’s modified Eagle’s medium
eGFP	Enhanced green fluorescent protein
ELISA	Enzyme-linked immunosorbent assay
F	Fusion protein
FBS	Fetal bovine serum
FP	Fusion peptide
G protein	Glycoprotein
GPO	Government Pharmaceutical Organization
HA	Hemagglutination
HN	Hemagglutinin–neuraminidase
hpi	Hours post-infection
HR	Heptapeptide repeat sequence
HRP	Horseradish peroxidase
HXP-S	Hexapro-spike
IACUC	Institutional Animal Care and Use Committee
ID50	Inhibitory dilution at which 50% neutralization is achieved
IM	Intramuscularly
IP	Intraperitoneal
NDV	Newcastle disease virus
NTD	N-terminal domain
PBS	Phosphate-buffered saline
PBST	1× PBS (pH 7.4) containing 0.1% (v/v) Tween-20
Pen Strep	Penicillin plus streptomycin
RBD	Receptor-binding domain
RBM	Receptor-binding motif
rcVSV	Replication-competent vesicular stomatitis virus
rcVSV-eGFP-CoV2-S	Replication-competent VSV engineered to express a GFP reporter and a SARS-CoV-2 spike protein in place of the native VSV-G protein
TM	Transmembrane domain
VOCs	Variants of concern